Insmed, Inc. (INSM) vs Royalty Pharma PLC (RPRX)
Insmed, Inc. and Royalty Pharma PLC are both Biotechnology companies. Royalty Pharma PLC is the larger, with a market value of $34.4B against $26.8B — 1.3× the size. Insmed, Inc. has negative trailing earnings, so its P/E is not meaningful; Royalty Pharma PLC trades at 40.1×. Insmed, Inc. grew revenue faster over the last twelve months: 185.8% against 10.0%. Royalty Pharma PLC has the higher net margin (32.0% vs −76.9%) and the higher return on invested capital (5.28% vs −329.2%). Across the 19 metrics below, Royalty Pharma PLC leads on 13 and Insmed, Inc. on 6.
Valuation
Profitability
| Metric | INSM | RPRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 83.46% | 100.00% | 65.16% |
| Operating margin | (73.89%) | 59.61% | 0.00% |
| Net margin | (76.94%) | 32.02% | 0.00% |
| Free cash flow margin | (71.00%) | 51.66% | 0.00% |
| Return on equity | (87.22%) | 8.42% | (57.72%) |
| Return on assets | (38.20%) | 4.26% | (49.22%) |
| Return on invested capital | (329.22%) | 5.28% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack